U.S. stock volatility: Apnimed surged on September 29 as NDA was accepted + Oxnimbi

Apnimed September 29th Surge Analysis

Keywords: NDA Acceptance, Oxnimbi

1. On September 8th, the company announced that the U.S. Food and Drug Administration had accepted the New Drug Application for AD109, proposed trade name Oxnimbi, and set the target review action date for February 28, 2027. The product has entered the regulatory review phase.

2. On August 25th, institutions initiated coverage on the company, assigning a “Buy” rating and a target price of $41. Data show that in its Phase III study, Oxnimbi reduced the apnea-hypopnea index by 34%–44%, targeting around 10.5 million diagnosed but untreated patients.

3. On August 3rd, the company completed an upsized initial public offering, issuing 13.8 million shares and raising a total of $220.8 million. The company is primarily engaged in the research, development, and commercialization of oral therapies for sleep-related breathing disorders, providing funding to support Oxnimbi’s potential commercialization.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)